PATRICIA BAXTER to Antineoplastic Agents
This is a "connection" page, showing publications PATRICIA BAXTER has written about Antineoplastic Agents.
Connection Strength
0.745
-
Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. Cancer Chemother Pharmacol. 2011 Apr; 67(4):809-12.
Score: 0.183
-
Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro Oncol. 2023 02 14; 25(2):386-397.
Score: 0.110
-
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). Pediatr Blood Cancer. 2021 04; 68(4):e28879.
Score: 0.095
-
Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. Cancer Res. 2020 12 01; 80(23):5393-5407.
Score: 0.093
-
Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. Pediatr Blood Cancer. 2021 02; 68(2):e28756.
Score: 0.093
-
Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors. Cancer Lett. 2020 11 28; 493:197-206.
Score: 0.093
-
Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Clin Cancer Res. 2018 05 01; 24(9):2159-2170.
Score: 0.078